BPC-157 + TB-500 Blend: Composition and Lab Handling
What a BPC-157 + TB-500 blend contains, how to calculate each peptide's concentration after reconstitution, how blends are tested and what is known.
A BPC-157 + TB-500 blend is a single lyophilized vial containing equal amounts of the two peptides, typically 5 mg + 5 mg or 10 mg + 10 mg. Researchers studying tissue-repair models use it because the two peptides are associated with different processes. For lab work, the main differences from single peptides are concentration arithmetic and identity testing.
For laboratory research use only. The compounds discussed are not approved for human or veterinary use and are not drugs, foods or cosmetics. This article summarises published research and is not medical advice.
Key points
- Composition: 1:1 BPC-157 and TB-500 by weight.
- After reconstitution, calculate the concentration of each peptide separately.
- The components differ by ~530 Da and in charge, so HPLC and MS can resolve both.
- Each peptide has its own literature; the combination itself has not been studied in peer-reviewed work that we know of.
- “Wolverine” is an informal marketing name, not a defined formulation.
Composition
| Vial | BPC-157 | TB-500 | Total peptide |
|---|---|---|---|
| 10 mg blend | 5 mg | 5 mg | 10 mg |
| 20 mg blend | 10 mg | 10 mg | 20 mg |
Our BPC-157 + TB-500 blend is supplied in both sizes, and the COA reports results for both components.
The two components
| BPC-157 | TB-500 | |
|---|---|---|
| Sequence | GEPPPGKPADDAGLV | Ac-LKKTETQ |
| Mass | 1419.5 g/mol | ~889 g/mol |
| Associated processes (preclinical) | Angiogenesis via VEGFR2–Akt–eNOS (Hsieh et al., 2017); growth hormone receptor up-regulation in tendon fibroblasts (Chang et al., 2014) | Thymosin beta-4 actin-binding region linked to cell migration and angiogenesis (Sosne et al., 2010) |
For BPC-157, a 2021 review from the original Zagreb group summarises skin and soft-tissue wound models in rats (Seiwerth et al., 2021). For TB-500, most biological data come from full-length thymosin beta-4 rather than the heptapeptide; see what is TB-500? and the comparison in BPC-157 vs TB-500.
Reconstitution: calculating each component
With blends, the most common mistake is quoting the total concentration when one component is meant. Divide each peptide’s amount by the volume:
| Vial | Solvent | BPC-157 | TB-500 | Per 0.1 mL (each) |
|---|---|---|---|---|
| 10 mg (5 + 5) | 1.0 mL | 5 mg/mL | 5 mg/mL | 0.5 mg |
| 10 mg (5 + 5) | 2.0 mL | 2.5 mg/mL | 2.5 mg/mL | 0.25 mg |
| 20 mg (10 + 10) | 2.0 mL | 5 mg/mL | 5 mg/mL | 0.5 mg |
| 20 mg (10 + 10) | 3.0 mL | 3.33 mg/mL | 3.33 mg/mL | 0.333 mg |
The peptide reconstitution calculator handles blends if you enter one component’s amount at a time. Both peptides dissolve readily in water. Bacteriostatic water suits a vial that will be sampled repeatedly; the general method is in how to reconstitute peptides.
How a blend is tested
Verifying a two-component vial requires showing that both peptides are present, correct and in the right ratio.
- Identity (MS): two distinct masses. Validated LC-MS methods exist for each peptide in biological matrices, for example a BPC-157 urine method with a 0.1 ng/mL detection limit (Cox et al., 2017) and a method for N-acetylated LKKTETQ and its metabolites (Ho et al., 2012). These demonstrate that both are well behaved in LC-MS.
- Purity and ratio (HPLC): BPC-157 is acidic and TB-500 basic, so they elute at clearly different retention times on reverse-phase columns. Peak areas, calibrated against standards, confirm the ratio.
- Appearance: white lyophilized powder; clear, colourless solution after reconstitution.
Storage
Store the sealed vial at −20 °C. After reconstitution, keep at 2–8 °C, protected from light, and avoid repeated freezing. The component that degrades faster limits the useful life of the whole solution. Details: how to store reconstituted peptides.
Open questions
- Do BPC-157 and N-acetylated LKKTETQ affect each other’s stability in solution over weeks at 2–8 °C? No published stability data cover the mixture.
- Is there any interaction at the level of the pathways each is associated with? This has not been tested in peer-reviewed work.
- Does the 1:1 weight ratio have a scientific basis? It reflects convention rather than a molar or dose-finding rationale; on a molar basis, a 1:1 weight ratio contains roughly 1.6 times more TB-500 molecules than BPC-157 molecules.
Related research
Frequently asked questions
What is in a BPC-157 and TB-500 blend?
Equal amounts of the two peptides in one lyophilized vial, for example 5 mg BPC-157 plus 5 mg TB-500 (10 mg total) or 10 mg plus 10 mg (20 mg total).
How do I calculate concentration for a blend?
Calculate each peptide separately. A 10 mg (5 + 5) vial reconstituted with 2 mL contains 2.5 mg/mL of BPC-157 and 2.5 mg/mL of TB-500, i.e. 5 mg/mL total peptide.
Can BPC-157 and TB-500 be mixed together?
They are chemically compatible in solution. Both are water-soluble, and they have opposite charge character and very different masses, which makes each easy to identify analytically. Premixed blends avoid the need to combine separate vials.
What is the 'Wolverine' blend?
‘Wolverine’ is an informal marketing name used online for BPC-157 and TB-500 combinations. It is not a scientific term and does not denote a defined ratio.
Has the BPC-157 and TB-500 combination been studied?
Each peptide has its own literature, but we are not aware of peer-reviewed studies testing the combination.
References
- Hsieh MJ, et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. J Mol Med (Berl). 2017. PMID: 27847966 https://pubmed.ncbi.nlm.nih.gov/27847966/
- Sosne G, et al. Biological activities of thymosin beta4 defined by active sites in short peptide sequences. FASEB J. 2010. PMID: 20179146 https://pubmed.ncbi.nlm.nih.gov/20179146/
- Ho EN, et al. Doping control analysis of TB-500, a synthetic version of an active region of thymosin β₄, in equine urine and plasma by liquid chromatography-mass spectrometry. J Chromatogr A. 2012. PMID: 23084823 https://pubmed.ncbi.nlm.nih.gov/23084823/
- Cox HD, et al. Detection and in vitro metabolism of the confiscated peptides BPC 157 and MGF R23H. Drug Test Anal. 2017. PMID: 28035768 https://pubmed.ncbi.nlm.nih.gov/28035768/
- Chang CH, et al. Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts. Molecules. 2014. PMID: 25415472 https://pubmed.ncbi.nlm.nih.gov/25415472/
- Seiwerth S, et al. Stable Gastric Pentadecapeptide BPC 157 and Wound Healing. Front Pharmacol. 2021. PMID: 34267654 https://pubmed.ncbi.nlm.nih.gov/34267654/
For laboratory research use only. The compounds discussed are not approved for human or veterinary use and are not drugs, foods or cosmetics. This article summarises published research and is not medical advice.
Sources
- Hsieh MJ, et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. J Mol Med (Berl). 2017. PMID: 27847966
- Sosne G, et al. Biological activities of thymosin beta4 defined by active sites in short peptide sequences. FASEB J. 2010. PMID: 20179146
- Ho EN, et al. Doping control analysis of TB-500, a synthetic version of an active region of thymosin β₄, in equine urine and plasma by liquid chromatography-mass spectrometry. J Chromatogr A. 2012. PMID: 23084823
- Cox HD, et al. Detection and in vitro metabolism of the confiscated peptides BPC 157 and MGF R23H. Drug Test Anal. 2017. PMID: 28035768
- Chang CH, et al. Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts. Molecules. 2014. PMID: 25415472
- Seiwerth S, et al. Stable Gastric Pentadecapeptide BPC 157 and Wound Healing. Front Pharmacol. 2021. PMID: 34267654